Vertaling van "trials in other " (Nederlands → Frans) :

Trials in other diseases, including type 2 diabetes and systemic juvenile idiopathic arthritis (SJIA), are also ongoing.
Des essais sont en cours dans d’autres maladies, comprenant le diabète de type 2 et l’arthrite idiopathique juvénile systémique (AJIS).

The antihypertensive and lipid lowering treatment to prevent heart attack trial (ALLHAT).JAMA 2002; 288: 2981-2997 (5) PAHOR M, PSATY B, ALERMAN M et al. Health outcomes associated with antagonists compared with other firstline antihypertensive therapies : a meta-analysis of randomised controlled trials.
The antihypertensive and lipid lowering treatment to prevent heart attack trial (ALLHAT). JAMA 2002 ; 288 : 2981-2997 (5) PAHOR M, PSATY B, ALERMAN M et al. Health outcomes associated with antagonists compared with other firstlineantihypertensive therapies : a meta-analysis of randomised controlled trials.

Trials are ongoing in other diseases in which IL-1 beta is believed to play an important role. Other diseases include refractory gout, chronic obstructive pulmonary disease (COPD), type 2 diabetes and systemic juvenile idiopathic arthritis (SJIA).
Des essais sont en cours dans d’autres maladies dans lesquelles IL-1β joue probablement un rôle important, telles que la goutte réfractaire, la broncho-pneumopathie chronique obstructive (BPCO), le diabète de type 2 et l’arthrite idiopathique juvénile systémique (AJIS).

Trials are underway in other age groups, including as young as two months, to protect against serogroups A, C, W-135 and Y found with this serious bacterial infection.
Des essais sont en cours dans d’autres tranches d’âges, dès l’âge de deux mois, pour les protéger contre les sérogroupes A, C, W-135 et Y que l’on trouve dans cette maladie bactérienne sévère.

JAMA 2002 ; 288 :2981-2997 (6) PAHOR M, PSATY B, ALERMAN M et al. Health outcomes associated with antagonists compared with other first-line antihypertensive therapies : a meta-analysis of randomised controlled trials.
JAMA 2002 ; 288 : 2981-2997 (6) PAHOR M, PSATY B, ALERMAN M et al. Health outcomes associated with antagonists compared with other first-line antihypertensive therapies : a meta-analysis of randomised controlled trials.

Afinitor is being studied in other tumor types with Phase III trials underway in tuberous sclerosis, breast cancer, gastric cancer, hepatocellular carcinoma and lymphoma.
Afinitor est également étudié pour d’autres types de tumeurs et des essais de phase III sont en cours dans la sclérose tubéreuse, le cancer du sein, le cancer de l’estomac, le carcinome hépatocellulaire et le lymphome.

Afinitor is also being studied in other tumor types with Phase III trials underway in tuberous sclerosis, breast cancer, gastric cancer, hepatocellular carcinoma and lymphoma.
Afinitor est également étudié pour d’autres types de tumeurs et des essais de phase III sont en cours avec des malades souffrant de tumeur neuroendocrine, de sclérose tubéreuse, de cancer du sein, de cancer de l’estomac, de carcinome hépatocellulaire et de lymphome.

The R&D (research and development) department of the FAMHP is responsible for the evaluation and approval of clinical research activities, ranging from the first “use” (concept) to extensive trials with medicines that are developed and carried out by university and other research centres and by the pharmaceutical industry.
The R&D (research and development) department of the FAMHP is responsible for the evaluation and approval of clinical research activities, ranging from the first “use” (concept) to extensive trials with medicines that are developed and carried out by university and other research centres and by the pharmaceutical industry.

In December 2009, Tasigna was submitted for US, European and other approvals worldwide for use in certain newly diagnosed chronic-phase CML patients based on data from the ENESTnd trial, the largest ever head-to-head comparison of a targeted therapy against Glivec.
Des demandes d’autorisations pour Tasigna ont été déposées, en décembre 2009, aux Etats-Unis, en Europe et dans d’autres pays en tant que traitement de certaines formes de LMC diagnostiquées précocement.

Trials are also ongoing in other diseases in which IL-1 beta may play an important role, including type 2 diabetes and systemic juvenile idiopathic arthritis (SJIA).
Des essais sont en cours pour d’autres maladies dans lesquelles IL-1β joue probablement un rôle important, telles le diabète de type 2 et l’arthrite idiopathique juvénile systémique (AJIS).